U.S. markets closed

Summit Therapeutics Inc. (SMMT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.02+0.15 (+3.08%)
At close: 4:00PM EST
Show:
Income Statement
Balance Sheet
Cash Flow
Annual
Subscribe to Premium to download historical data

Income Statement

All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Breakdown
ttm
1/31/2019
1/31/2018
1/31/2017
Total Revenue
3,040
56,413
35,980
2,880
Cost of Revenue
-
24.9197
97.6673
-
Gross Profit
-
56,388
35,882
-
Operating Expense
33,896
47,262
51,165
33,279
Operating Income
-30,881
9,126
-15,283
-30,399
Net Non Operating Interest Income Expense
-154.9158
3,101
2,735
-1,067
Other Income Expense
-
-5,628
-2,871
-666.225
Pretax Income
-31,598
6,598
-15,419
-32,133
Tax Provision
-4,469
-3,274
-5,325
-5,420
Net Income Common Stockholders
-27,129
9,872
-10,094
-26,713
Diluted NI Available to Com Stockholders
-27,129
9,872
-10,094
-26,713
Basic EPS
-
0
0
0
Diluted EPS
-
0
0
0
Basic Average Shares
-
85,702
65,434
61,549
Diluted Average Shares
-
85,702
65,434
61,549
Total Operating Income as Reported
-31,444
3,498
-18,153
-31,065
Rent Expense Supplemental
-
-
409.0703
266.24
Total Expenses
33,921
47,287
51,263
33,279
Net Income from Continuing & Discontinued Operation
-27,129
9,872
-10,094
-26,713
Normalized Income
-26,093
13,980
-8,215
-26,159
Interest Income
-3,531
5.2462
15.5702
9.9996
Interest Expense
275.0338
556.102
1,067
1,077
Net Interest Income
-154.9158
3,101
2,735
-1,067
EBIT
-31,323
7,155
-14,351
-31,055
EBITDA
-29,880
-
-
-
Reconciled Cost of Revenue
-
24.9197
97.6673
-
Reconciled Depreciation
1,443
1,493
348.2052
72.4973
Net Income from Continuing Operation Net Minority Interest
-27,129
9,872
-10,094
-26,713
Total Unusual Items Excluding Goodwill
-1,207
-5,628
-2,871
-666.225
Total Unusual Items
-1,207
-5,628
-2,871
-666.225
Normalized EBITDA
-28,674
14,275
-11,133
-30,316
Tax Rate for Calcs
0
0
0
0
Tax Effect of Unusual Items
-170.6597
-1,520
-991.3782
-112.3722